Safety and efficacy of Tranilast for the treatment of relapsed or resistant lymphoid tumors; a pilot study

Safety and efficacy of Tranilast for the treatment of relapsed or resistant lymphoid tumors; a pilot study - Tranilast for lymphoid tumors; a pilot study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008210

Enrollment

Registered

2012-06-19

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or resistant lymphoid tumors

Interventions

Tranilast 100mg TID, 200mg TID, 300mg TID

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Relapsed or resistant lymphoid tumor 2, Aged 20 years or over 3, ECOG PS 0-3 4, Written informed consent

Exclusion criteria

Exclusion criteria: 1, Allergy to Tranilast 2, Severe uncontrollable diabetes or infection 3, Active double cancers 4, Pregnant or lactating women or women of childbearing potential 5, AST,ALT>5xULN, T-Bil 3XULN 6, Cre>3xULN 7, Psychosis 8, Inadequate condition as diagnosed by primary physician

Design outcomes

Primary

Measure	Time frame
Safety of 2 weeks administration of Tranilast for patients with lymphoid tumors	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026